WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
- Invasive fungal infections (IFIs) are an important cause of morbidity
and mortality in children with cancer or diseases that require
hematopoietic stem cell transplantation (HSCT) for their cure.
- The use of azoles for antifungal prophylaxis after familial allogeneic
stem cell transplantation in children (SCT) is hindered by adverse
events and drug–drug interactions especially in children affected by
sickle cell disease (SCD).
- Some studies suggest the use of micafungin every 48 h as a safe
alternative in pediatric patients to facilitate its administration;
however, those series are small.